A randomized parallel-group double-blind placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo both in combination with a glucocorticoid taper

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Giant Cell Arteritis [gca]
  • Age: Between 50 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Signed informed consent must be obtained prior to participation in the study.
    2. Patient must be able to understand and communicate with the investigator and comply with the requirements of the study.
    3. Male or non-pregnan

You may not be eligible for this study if the following are true:

    1. Pregnant or nursing (lactating) women .
    2. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.